-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
BioXcel Therapeutics announced today that the U.
Up to 25% of people with schizophrenia and bipolar disorder experience agitation, which can range from 10 to 17 episodes per year, placing a heavy burden on patients, caregivers, and the healthcare system
Igalmi is a sublingual film formulation of the selective alpha2 adrenergic agonist dexmedetomidine, which is rapidly acting upon oral absorption
FDA approval is based on the results of two pivotal, randomized, double-blind, placebo-controlled Phase 3 clinical trials
▲Igalmi's Phase 3 clinical trial results (Image source: BioXcel's official website)
"Igalmi is the first new acute therapy in nearly 10 years to treat agitation associated with schizophrenia or bipolar I/II disorder and represents a differentiated model for helping patients manage this symptom
References:
[1] BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults.
[2] A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder and Schizophrenia.